To determine the efficiency of the anti-CCR7 therapy in the early stages of tumor implantation we established two groups of mice: 1) the treated group (n = 5), that received intraperitoneally 200 μg of anti-CCR7 mAb on days 2, 6 and 10 after the Granta-519 cells inoculation, and 2) the control group (n = 5), that was treated with PBS following the same schedule than that of the treated group. This evidence concerns the gene CCR7 and neoplasm.